Investment
Features
FeesSafety
Academy
More
Pluang+

Japan approves Dupixent as first targeted treatment for adults with bullous pemphigoid

Market News
24 Mar 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Japan's Ministry of Health has approved Dupixent (dupilumab) for treating adults with moderate-to-severe bullous pemphigoid (BP), a chronic skin disease. The approval follows a Phase 2/3 trial showing Dupixent patients had over four times more sustained disease remission at 36 weeks compared to placebo. Dupixent, already approved for several other inflammatory diseases in Japan, offers a non-immunosuppressant option targeting key inflammatory pathways. This expands treatment options for BP, a condition with limited therapies and significant patient burden.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App